Belite Bio (BLTE)
(Delayed Data from NSDQ)
$48.35 USD
+0.23 (0.48%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $48.10 -0.25 (-0.52%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BLTE 48.35 +0.23(0.48%)
Will BLTE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BLTE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BLTE
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
BLTE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BLTE
Belite Bio to Present at the JonesHealthcare Seaside Summit
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
Buy Rating Affirmed for Belite Bio, ADR on Tinlarebant’s Promising Regulatory and Clinical Prospects
Belite Bio granted Sakigake Designation by Japan MHLW
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan